SAN FRANCISCO – Rituximab is, for now, the first-line option for Sjögren’s syndrome patients with systemic symptoms severe enough to require biologic…
www.rheumatologynews.com|By M. ALEXANDER OTTO
Sjogren’s Syndrome US treatment guidelines: Rituximab is first line.
Towards personalised treatment in primary Sjögren’s syndrome: predicting response to Rituximab
ncbi.nlm.nih.gov|By Delli K , et al.
A high pretreatment number of CD20+ B cells/mm(2) parotid gland parenchyma predicts better responsiveness of patients with pSS to RTX treatment.